CHF Solutions (CHFS) Presents At Ladenburg Thalmann Healthcare Conference - Slideshow

Financial Highlights - CHF Solutions had approximately 27 million common shares outstanding with a market cap of approximately $6 million as of September 16, 2019 [6] - The company experienced 9 consecutive quarters of double-digit revenue growth [6] - Year 2018 revenue grew 41% compared to 2017 [6] - Q2 2019 revenue was up 53% from Q2 2018 and 38% from Q1 2019 [6] - As of June 30, 2019, CHF Solutions had $74 million in cash on hand and no debt [6] Aquadex FlexFlow System - Aquadex FlexFlow removes 40% more fluid than conventional diuretic drug therapy [24] - Aquadex FlexFlow is associated with a 53% reduction in the risk of heart failure rehospitalization at 90 days compared to diuretics [24] Market Opportunity - The addressable US market segments for Aquadex FlexFlow total over $2 billion annually [80] - The company estimates a $950 million market opportunity in critical care, $900 million in heart failure, and $115 million in pediatrics [32] - There are over 6 million people in the US suffering from heart failure [36]